Decision: Favourable

Study Title:

A phase III, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the safety and efficacy of AMX0035 versus placebo for 48-week treatment of adult patients with Amyotrophic Lateral Sclerosis (ALS)

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Prof Orla Hardiman

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Amylyx Pharmaceuticals

Scroll to Top
Skip to content